RDNT
RadNet, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.78
P/S
2.08
EV/EBITDA
21.04
DCF Value
$-37.12
FCF Yield
-4.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
11.2%
Operating Margin
3.0%
Net Margin
-0.9%
ROE
-1.9%
ROA
-0.7%
ROIC
1.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $547.7M | $-597.0K | $-0.01 |
| FY 2025 | $2.04B | $-18.7M | $-0.25 |
| Q3 2025 | $522.9M | $5.4M | $0.07 |
| Q2 2025 | $498.2M | $14.5M | $0.19 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.53
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.